Aquestive Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $75.00M, a 7452.87% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $4.41M.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $993.00K, a 26.99% decline year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $642.00K, a 89.68% decline year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $9.46M, a 125.55% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $4.20M, a 86.49% decline from fiscal 2021.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $31.07M, a 375.93% increase from fiscal 2020.
- Aquestive Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $6.53M, a 82.75% decline from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-03-31 | $75.00M 10-Q · filed 2025-08-11 | |
| 2023-12-31 | $9.46M 10-K · filed 2024-03-05 | |
| 2023-06-30 | $4.41M 10-Q · filed 2024-08-06 | |
| 2023-03-31 | $993.00K 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $4.20M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $642.00K 10-Q · filed 2022-11-01 | |
| 2022-03-31 | $1.36M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $31.07M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $6.22M 10-Q · filed 2021-11-02 | |
| 2021-06-30 | $9.24M 10-Q · filed 2021-11-02 | |
| 2021-03-31 | $10.20M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $6.53M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $37.84M 10-K · filed 2021-03-09 | |
| 2018-12-31 | $68.71M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $68.71M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |